(redirected from elvitegravir)
Also found in: Medical.
Related to elvitegravir: dolutegravir, cobicistat


 (ĕm′trĭ-sĭt′ə-bēn′, -sī′tə-)
An antiviral drug, C8H10FN3O3S, that is a nucleoside reverse transcriptor inhibitor and is used in combination with other drugs to treat HIV infection or to reduce the risk of HIV infection.

[emtri- (probably Em(ory) University, where the drug was discovered + Tri(angle) Pharmaceuticals, company to which it was licensed) + -citabine, nucleoside analog antiviral and anticancer drug suff.; see zalcitabine.]


n emtricitabina
Mentioned in ?
References in periodicals archive ?
For Gilead, Cy572 could represent a strong competitor for its new combination pills, including a four-in-one "Quad" tablet in Phase III development that contains elvitegravir.
The recent IN inhibitors, raltegravir and elvitegravir, belong to the latter class of compounds.
Elvitegravir is the most recent Gilead drug to enter Phase III and is the latest drug in the promising new class of drugs known as "Integrase inhibitors.
Food and Drug Administration today approved Genvoya (a fixed-dose combination tablet containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide) as a complete regimen for the treatment of HIV-1 infection in adults and pediatric patients 12 years of age and older.
Combined results of identical phase 3, double-blind, double-dummy trials found TAF virologically noninferior to TDF when either came packed in a single tablet with elvitegravir, cobicistat, and emtricitabine.
The revision builds on MPP's long-term collaboration with Gilead Sciences for the production of TDF, emtricitabine (FTC), cobicistat (COBI), and elvitegravir (EVG), as well as a single tablet regimen of all four ARVs.
He gave three examples in the development pipeline--rilpivirine, elvitegravir, and S/GSK1349572--in a presentation at a meeting on HIV management sponsored by the University of California, San Francisco.
With raltegravir having a twice-daily dosing schedule and elvitegravir being once daily, but with ritonavir boosting, it will be interesting to see what predicts greater usage.
Lot No 13 - Elvitegravir / Cobicistat / emtricitabine / tenofovir disoproxil | 150/150/200 / 245mg | Tablet | 30 - Number of packages 1100
Prescribing information for three licensed integrase inhibitors--dolutegravir, elvitegravir, and raltegravir--does not list insulin resistance, glucose abnormalities, or diabetes mellitus as side effects.